CUSIP NO. 032346 10 8 Page 1 of 6 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No. 2)(1)
Amylin Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
032346 10 8
--------------------------------------------------------------------------------
(CUSIP Number)
Kathleen K. Schoemaker John C. MacMurray, Esq.
Domain Associates, L.L.C. Reboul, MacMurray, Hewitt,
One Palmer Square Maynard & Kristol
Princeton, New Jersey 08452 45 Rockefeller Plaza
Tel. (609) 683-5656 New York, New York 10111
Tel. (212) 841-5700
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 8, 2000
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box [ ].
----------
(1)The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page. The information required on
the remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to
all other provisions of the Act.
<PAGE>
CUSIP NO. 032346 10 8 Page 2 of 6 Pages
--------------------------------------------------------------------------------
1) Name of Reporting Person Domain Partners
I.R.S. Identification IV, L.P.
No. of Above Person
(If an Entity)
--------------------------------------------------------------------------------
2) Check the Appropriate Box (a) [x]
if a Member of a Group (b) [ ]
--------------------------------------------------------------------------------
3) SEC Use Only
--------------------------------------------------------------------------------
4) Source of Funds Not Applicable
--------------------------------------------------------------------------------
5) Check if Disclosure of
Legal Proceedings is Not Applicable
Required Pursuant to
Items 2(d) or 2(e)
--------------------------------------------------------------------------------
6) Citizenship or Place
of Organization Delaware
--------------------------------------------------------------------------------
Number of 7) Sole Voting 4,115,046 shares of
Shares Beneficially Power Common Stock
Owned by Each
Reporting Person
With
---------------------------------------------
8) Shared Voting
Power -0-
---------------------------------------------
9) Sole Disposi- 4,115,046 shares of
tive Power Common Stock
---------------------------------------------
10) Shared Dis-
positive Power -0-
---------------------------------------------
11) Aggregate Amount Beneficially 4,115,046 shares of
Owned by Each Reporting Person Common Stock
--------------------------------------------------------------------------------
12) Check if the Aggregate
Amount in Row (11)
Excludes Certain Shares
--------------------------------------------------------------------------------
13) Percent of Class
Represented by 6.5%
Amount in Row (11)
--------------------------------------------------------------------------------
14) Type of Reporting
Person PN
<PAGE>
CUSIP NO. 032346 10 8 Page 3 of 6 Pages
1) Name of Reporting Person DP IV Associates,
I.R.S. Identification L.P.
No. of Above Person
(If an Entity)
--------------------------------------------------------------------------------
2) Check the Appropriate Box (a) [x]
if a Member of a Group (b) [ ]
--------------------------------------------------------------------------------
3) SEC Use Only
--------------------------------------------------------------------------------
4) Source of Funds Not Applicable
--------------------------------------------------------------------------------
5) Check if Disclosure of
Legal Proceedings is Not Applicable
Required Pursuant to
Items 2(d) or 2(e)
--------------------------------------------------------------------------------
6) Citizenship or Place
of Organization Delaware
--------------------------------------------------------------------------------
Number of 7) Sole Voting 99,159 shares of
Shares Beneficially Power Common Stock
Owned by Each
Reporting Person
With
---------------------------------------------
8) Shared Voting
Power -0-
---------------------------------------------
9) Sole Disposi- 99,159 shares of
tive Power Common Stock
---------------------------------------------
10) Shared Dis-
positive Power -0-
---------------------------------------------
11) Aggregate Amount Beneficially 99,159 shares of
Owned by Each Reporting Person Common Stock
--------------------------------------------------------------------------------
12) Check if the Aggregate
Amount in Row (11)
Excludes Certain Shares
--------------------------------------------------------------------------------
13) Percent of Class
Represented by 0.2%
Amount in Row (11)
--------------------------------------------------------------------------------
14) Type of Reporting
Person PN
<PAGE>
CUSIP NO. 032346 10 8 Page 4 of 6 Pages
AMENDMENT NO. 2 TO SCHEDULE 13D
-------------------------------
Reference is hereby made to the statement on Schedule 13D originally
filed with the Securities and Exchange Commission (the "Commission") on April 2,
1999 and Amendment No. 1 thereto filed on June 26, 2000 (as so amended, the
"Schedule 13D"). Terms defined in the Schedule 13D are used herein as so
defined.
Item 2. Identity and Background.
Item 2 of the Schedule 13D is hereby amended to remove DP II as a
Reporting Person, as DP II no longer owns any securities of the Issuer, as
reported in Amendment No. 1 to the Schedule 13D.
Item 5. Interest in Securities of the Issuer.
Item 5 of the Schedule 13D is hereby amended and restated to read in
its entirety as follows:
The following information is based on a total of 62,924,000 shares of
Common Stock outstanding as of August 4, 2000, as reported in the Issuer's
Report on Form 10-Q for the period ended June 30, 2000 filed with the Commission
on August 14, 2000.
(a)
DP IV
DP IV owns 4,115,046 shares of Common Stock, or approximately 6.5% of
the Common Stock outstanding. OPSA IV, as the general partner of DP IV, may be
deemed to indirectly beneficially own the shares of Common Stock owned by DP IV.
DP IV A
DP IV A owns 99,159 shares of Common Stock, or approximately 0.2% of
the Common Stock outstanding. OPSA IV, as the general partner of DP IV A, may be
deemed to indirectly beneficially own the shares of Common Stock owned by DP IV
A.
OPSA IV
In addition to the shares of Common Stock referred to above under DP
IV and DP IV A, OPSA IV directly beneficially owns
<PAGE>
CUSIP NO. 032346 10 8 Page 5 of 6 Pages
114,486 shares of Common Stock, or approximately 0.2% of the Common Stock
outstanding.
Managing Members of OPSA IV
(i) James C. Blair owns 89,040 shares of Common Stock, including
21,370 shares issuable upon exercise of stock options that are presently
exercisable or exercisable within 60 days of the date of this statement, or
approximately 0.1% of the Common Stock outstanding.
(ii) Jesse I. Treu owns 28,792 shares of Common Stock, or less than
0.1% of the Common Stock outstanding.
(iii) Brian H. Dovey owns 28,792 shares of Common Stock, or less than
0.1% of the Common Stock outstanding.
(iv) Kathleen K. Schoemaker owns 3,131 shares of Common Stock, or less
than 0.1% of the Common Stock outstanding.
(v) Arthur J. Klausner owns 1,500 shares of Common Stock, or less than
0.1% of the Common Stock outstanding.
(b) The managing members of OPSA IV may be deemed to share the power
to vote or direct the voting of and to dispose or direct the disposition of the
Common Stock owned by DP IV and DP IV A. Each of the managing members of OPSA IV
disclaims beneficial ownership of all shares of Common Stock other than the
shares of Common Stock he or she owns directly, or by virtue of his or her
indirect pro rata interest, as a managing member of OPSA IV, in the Common Stock
owned by DP IV and/or DP IV A.
(c) On September 8, 2000, DP IV distributed 1,000,000 shares of Common
Stock to its partners, including 114,486 shares to its general partner, OPSA IV.
Also on September 8, 2000, DP IV A sold 23,400 shares of Common Stock in open
market transactions, at a price of $13.41 per share.
(d) Except as described in this statement, no person has the power to
direct the receipt of dividends on, or the proceeds from sales of, the shares of
Common Stock owned by DP IV or DP IV A.
(e) Not applicable.
<PAGE>
CUSIP NO. 032346 10 8 Page 6 of 6 Pages
Signature
---------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: September 14, 2000
DOMAIN PARTNERS IV, L.P.
By: One Palmer Square Associates
IV L.L.C., General Partner
By /s/ Kathleen K. Schoemaker
---------------------------------
Managing Member
DP IV ASSOCIATES, L.P.
By: One Palmer Square Associates
IV L.L.C., General Partner
By /s/ Kathleen K. Schoemaker
---------------------------------
Managing Member
